Cure8 research brief
Quantitative, rapid stool tests could make it easier to track intestinal inflammation without central lab delays. If translated to clinical use, SERS-enhanced lateral-flow assays might allow more frequent, point-of-care monitoring of IBD activity using established stool biomarkers.
Researchers, diagnostic developers, clinicians interested in IBD monitoring, and patient advocates tracking biomarker tools.
This study reports a proof-of-concept lateral flow immunoassay that uses surface-enhanced Raman scattering (SERS) nanotags to detect two stool biomarkers associated with intestinal inflammation: lactoferrin and myeloperoxidase.
The researchers developed singleplex and duplex test strips and applied Raman-mapping signal analysis methods to reduce stool-matrix background and move the readout from qualitative toward quantitative.
The assays achieved analytical limits of detection (3.2 ng/mL for lactoferrin; 5.0 ng/mL for myeloperoxidase) and limits of quantification lower than typical stool biomarker “normal” levels, and used a ratiometric approach to measure both biomarkers simultaneously on one strip.
The work focuses on analytical method development (signal extraction and thresholding) rather than clinical validation with patient samples. This is an abstract-level report of laboratory (bench) research in an academic journal.
It demonstrates technical feasibility and improved signal-analysis approaches for quantitative lateral-flow detection of IBD biomarkers, but it does not establish clinical performance, real-world usability, or regulatory status.
Findings are from laboratory proof-of-concept work using artificial stool matrix and analytical performance metrics reported in the abstract; clinical validation and real-sample performance are not presented in this report.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study describes a new urine-based fluorescent biosensor that detected inflamed intestinal sites and tracked treatment response earlier and more sensitively than fecal calprotectin in a mouse model of IBD, which could...
Blood markers that correlate with endoscopic healing could help track inflammation noninvasively and may reduce the frequency of endoscopy if validated. For people with IBD, better blood-based tools could make monitoring...
The study points to serum protein panels and tissue expression of glypican-6 (GPC6) as potential tools to diagnose or predict intestinal strictures in Crohn disease, which could help detect fibrosis earlier and guide...
